-
Mashup Score: 0
The American Journal of Hematology publishes research in blood diseases in humans & animal model, covering all hematological diseases including leukemia, hemostasis and thrombosis.
Source: onlinelibrary.wiley.comCategories: General Medicine NewsTweet
-
Mashup Score: 0
A tenth of patients die within 60 days of diagnosis of MM. Infection and renal failure are the main direct causes of early mortality, which cannot be accurately predicted by presenting prognostic features. All patients should be considered at high risk of death during induction therapy.
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine NewsTweet-
Myeloma patients may get infections early (induction; [2005] Augustson et al. @JCO_ASCO https://t.co/g8N8VkmuKT) or later (Lim et al. [2021] CLML https://t.co/CDl33P6aQG) #mmsm #IDonc
-
-
Mashup Score: 2Epidemiology and Risks of Infections in Patients With Multiple Myeloma Managed With New Generation Therapies - 5 day(s) ago
Micro-AbstractThis study evaluated the epidemiology and infection risks in patients with multiple myeloma managed with second-generation therapies and monoclonal antibodies. Clinical records of 148 patients with multiple myelomawere reviewed to capture demographics, treatments, infection episodes, and outcomes. Viral infections now constitute the majority of infections, and a higher risk patient group (proteasome inhibitor-treated and > 4 lines of therapy) has been identified.
Categories: General Medicine NewsTweet-
Epidemiology and Risks of Infections in Patients w/ Multiple Myeloma Managed With New Generation Therapies [Feb 17, 2021] Lim et al. CLML https://t.co/CDl33P6aQG #mmsm #IDonc n=148 Australian Pts w/ 345 infections https://t.co/D9kVr1b1pr
-
-
Mashup Score: 4Listeria Susceptibility in Patients With Multiple Myeloma Receiving Daratumumab-Based Therapy - 5 day(s) ago
This case-control study examines the association of Listeria monocytogenes susceptibility with the receipt of daratumamab-based therapy in Canadian patients with multiple myeloma.
Source: jamanetwork.comCategories: General Medicine NewsTweet-
Listeria Susceptibility in Patients With Multiple Myeloma Receiving Daratumumab-Based Therapy [Nov 27, 2019] Khan et al. @JAMAOnc https://t.co/TH1HM3T6nr #mmsm #IDonc HT @timfenske
-
-
Mashup Score: 1
Immunogenicity And Safety Of The 13-Valent Pneumococcal Conjugate Vaccine In Patients With Monoclonal Gammopathy Of Undetermined Significance – Relationship With Selected Immune And Clinical Parameters Marcin Pasiarski,1,2 Barbara Sosnowska-Pasiarska,3 Ewelina Grywalska,4,5 Agnieszka Stelmach-Gołdyś,1 Artur Kowalik,6 Stanisław Góźdź,2,7 Jacek Roliński4,5 1Department of Hematology, Holycross Cancer Center, Kielce, Poland; 2Department of Immunology, Faculty of Health Sciences, Jan Kochanowski University, Kielce, Poland; 3Department of Oncocardiology, Holycross Cancer Center, Kielce, Poland; 4Department of Clinical Immunology and Immunotherapy, Medical University of Lublin, Lublin, Poland; 5Clinical Immunology Department, St. John’s Cancer Center, Lublin, Poland; 6Department of Molecular Diagnostics, Holycross Cancer Center, Kielce, Poland; 7Department of Oncology, Holycross Cancer Center, Kielce, PolandCorrespondence: Ewelina GrywalskaDepartment of Clinical Immunology and Immunotherapy,
Source: www.dovepress.comCategories: General Medicine NewsTweet-
Immunogenicity and Safety Of The 13-Valent Pneumococcal Conjugate Vaccine [PCV13] In Patients with MGUS – Relationship with Selected Immune And Clinical Parameters [Oct 9, 2019] Pasiarski et al. Clinical Interventions in Aging https://t.co/sj46MHQr3G #mmsm #IDonc https://t.co/kncKOk3xP4
-
-
Mashup Score: 1
Open access journal of the Ferrata-Storti Foundation, a non-profit organization Open access journal of the Ferrata-Storti Foundation, a non-profit organization Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Hematology, Cancer Center Amsterdam, Amsterdam Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Hematology, Cancer Center Amsterdam, Amsterdam University Medical Center, Laboratory of Translational Immunology, Utrecht Erasmus Medical Center, Department of Viroscience, National
Source: haematologica.orgCategories: General Medicine NewsTweet-
Effect of daratumumab on normal plasma cells, polyclonal immunoglobulin levels, and vaccination responses in extensively pre-treated multiple myeloma patients [Sep 26, 2019] Frerichs et al. @Haematologica https://t.co/UBMNRjfZkz #mmsm #IDonc HT @Taxkourel https://t.co/OjFlv1CgQX
-
-
Mashup Score: 0
A tenth of patients die within 60 days of diagnosis of MM. Infection and renal failure are the main direct causes of early mortality, which cannot be accurately predicted by presenting prognostic features. All patients should be considered at high risk of death during induction therapy.
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet-
Myeloma patients may get infections early (induction; [2005] Augustson et al. @JCO_ASCO https://t.co/g8N8VkmuKT) or later (Lim et al. [2021] CLML https://t.co/CDl33P6aQG) #mmsm #IDonc
-
-
Mashup Score: 4Multiple Myeloma | NEJM - 7 month(s) ago
Multiple myeloma, a plasma-cell neoplasm characterized by skeletal destruction, renal failure, anemia, and hypercalcemia, remains incurable. However, recent advances in its treatment, in particular…
Source: www.nejm.orgCategories: General Medicine News, Hem/OncsTweet-
Infections are an important cause of morbidity & leading cause of death in myeloma [Oct 28, 2004] @RobertK68033234 & @VincentRK @NEJM https://t.co/D8cFdRX3nV #mmsm #IDonc
-
-
Mashup Score: 0
Pneumococcal vaccination: the response of patients with multiple myeloma
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet-
Lazarus et al. 1980 @amjmed https://t.co/2jdVrSNCt5 #mmsm #IDonc ~30% signif Ab response to immunization (14-valent pneumococcal) - low cost, low risk "...may be prudent medical practice to vaccinate patients with myeloma."
-
-
Mashup Score: 0
A tenth of patients die within 60 days of diagnosis of MM. Infection and renal failure are the main direct causes of early mortality, which cannot be accurately predicted by presenting prognostic features. All patients should be considered at high risk of death during induction therapy.
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet-
Myeloma patients may get infections early (induction; [2005] Augustson et al. @JCO_ASCO https://t.co/g8N8VkmuKT) or later (Lim et al. [2021] CLML https://t.co/CDl33P6aQG) #mmsm #IDonc
-
Prevention of infections including vaccination strategies in multiple myeloma [Oct 17, 2022] Ludwig & @myelomaMD https://t.co/t6hCCDoY1i #mmsm #IDonc